Guru Sonpavde

31PUBLICATIONS
226CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (31)

|May 28, 2026
Unleashing Precision Oncology in the Development of Human Epidermal Growth Factor Receptor 2-Targeted Antibody Drug Conjugates for Urothelial Carcinoma.

|Jan 13, 2026
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.

Timothy A Yap, Randy F Sweis, Ulka Vaishampayan

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Dec 09, 2025
Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology.

Jason R Brown, Guru Sonpavde

|Sep 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer.

Andrea Necchi, Matthew D Galsky, Nazli Dizman

|Jun 19, 2025
Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao et al.

Christopher Graser, Thomas O McDonald, Paul J Catalano

Pageof 6

Frequent Collaborators

5 joint publications

Toni K Choueiri

5 joint publications

Andrea Necchi

4 joint publications

Philippe E Spiess

4 joint publications

Talal El Zarif